Mason Street Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-6,664
| Closed | -$281K | – | 398 |
|
|
2020
Q4 | $281K | Sell |
6,664
-38
| -0.6% | -$1.6K | ﹤0.01% | 1337 |
|
|
2020
Q3 | $307K | Buy |
6,702
+619
| +10% | +$28.4K | 0.01% | 1237 |
|
|
2020
Q2 | $305K | Buy |
6,083
+518
| +9% | +$26K | 0.01% | 1233 |
|
|
2020
Q1 | $286K | Hold |
5,565
| – | – | 0.01% | 1165 |
|
|
2019
Q4 | $344K | Buy |
5,565
+152
| +3% | +$9.4K | 0.01% | 1240 |
|
|
2019
Q3 | $325K | Buy |
5,413
+95
| +2% | +$5.7K | 0.01% | 1241 |
|
|
2019
Q2 | $449K | Buy |
5,318
+260
| +5% | +$22K | 0.01% | 1127 |
|
|
2019
Q1 | $483K | Buy |
5,058
+172
| +4% | +$16.4K | 0.01% | 1150 |
|
|
2018
Q4 | $346K | Buy |
4,886
+235
| +5% | +$16.6K | 0.01% | 1163 |
|
|
2018
Q3 | $397K | Buy |
4,651
+478
| +11% | +$40.8K | 0.01% | 1184 |
|
|
2018
Q2 | $484K | Buy |
4,173
+188
| +5% | +$21.8K | 0.01% | 1095 |
|
|
2018
Q1 | $322K | Buy |
3,985
+272
| +7% | +$22K | 0.01% | 1194 |
|
|
2017
Q4 | $218K | Buy |
3,713
+97
| +3% | +$5.7K | ﹤0.01% | 1311 |
|
|
2017
Q3 | $169K | Buy |
3,616
+189
| +6% | +$8.83K | ﹤0.01% | 1359 |
|
|
2017
Q2 | $123K | Buy |
3,427
+178
| +5% | +$6.39K | ﹤0.01% | 1409 |
|
|
2017
Q1 | $100K | Buy |
3,249
+212
| +7% | +$6.53K | ﹤0.01% | 1437 |
|
|
2016
Q4 | $102K | Buy |
3,037
+176
| +6% | +$5.91K | ﹤0.01% | 1427 |
|
|
2016
Q3 | $76K | Buy |
2,861
+267
| +10% | +$7.09K | ﹤0.01% | 1436 |
|
|
2016
Q2 | $57K | Buy |
2,594
+239
| +10% | +$5.25K | ﹤0.01% | 1454 |
|
|
2016
Q1 | $69K | Buy |
2,355
+244
| +12% | +$7.15K | ﹤0.01% | 1404 |
|
|
2015
Q4 | $70K | Buy |
2,111
+181
| +9% | +$6K | ﹤0.01% | 1388 |
|
|
2015
Q3 | $70K | Buy |
+1,930
| New | +$70K | ﹤0.01% | 1368 |
|